Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides

US9617258B2 · kind B2 · utility

Assignee

• PFIZER INC. · US

Inventors

• Atli Thorarensen · O'Fallon, US
• Matthew Frank Brown · Stonington, US
• Agustin Casimiro-Garcia · Concord, US
• Ye Che · Groton, US
• Jotham Wadsworth Coe · Niantic, US
• Mark E. Flanagan · Gales Ferry, US
• Adam Matthew Gilbert · Congers, US
• Matthew Merrill Hayward · Old Lyme, US
• Jonathan David Langille · Quaker Hill, US
• Justin Ian Montgomery · Ledyard, US
• Jean-Baptiste Telliez · Lexington, US
• Rayomand Jal Unwalla · Eagleville, US
• John I. Trujillo · Ledyard, US

Key dates

• Filing date: Dec 3, 2014
• Grant date: Apr 11, 2017
• Expiry date: Dec 3, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof, having the structure:or a pharmaceutically acceptable salt or solvate thereof, or an enantiomer or diastereomer thereof, as set forth in the Description. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.